These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8864448)

  • 1. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.
    Emmanouilides CE; Luo J; Baldwin G; Buckley D; Lau P; Lopez E; Tabibzadeh S; Yu J; Wolin M; Rigor R; Territo M; Black AC
    Bone Marrow Transplant; 1996 Aug; 18(2):369-75. PubMed ID: 8864448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
    Stark J; Weiss L; Slavin S
    Isr J Med Sci; 1992 Nov; 28(11):767-72. PubMed ID: 1468887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
    Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
    J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes.
    Contassot E; Robinet E; Angonin R; Laithier V; Bittencourt M; Pavy JJ; Cahn JY; Hervé P; Tiberghien P
    Bone Marrow Transplant; 1998 Dec; 22(11):1097-102. PubMed ID: 9877273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD.
    Morohashi T; Ogasawara K; Kitaichi N; Iwabuchi K; Onoé K
    Bone Marrow Transplant; 2000 Nov; 26(10):1069-76. PubMed ID: 11108305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
    Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
    Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
    Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
    Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.